Swipe Left For English News
1
中国生物制药将委托并通过药明生物一体化技术平台进行一个单克隆抗体（mAb）的发现，该单抗靶点未披露
2
药明生物在一体化研究服务中推出全新定制化模式，加速赋能客户国际化战略
上海
2024年12月30日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）今日宣布与中国领先的创新研发企业中国生物制药（1177.HK）达成研究服务合作协议，以赋能其发现一款靶点未披露的“First-in-Class”单克隆抗体。
根据协议，药明生物将通过领先的抗体发现技术平台（如单B细胞技术平台）提供一体化研究服务，根据中国生物制药指定的靶点生成抗体，并进行先导抗体发现、优化以及可开发性评估等，筛选出处于临床前开发阶段的最佳候选单抗。中国生物制药将拥有该单抗的独家权益，并负责后续的新药临床试验申请（IND）、临床试验以及产品商业化。药明生物将根据项目开发和商业化进展收到相应付款。
陈智胜 博士
首席执行官
药明生物
我们很高兴通过一体化技术平台赋能中国生物制药发现‘First-in-Class’抗体。这一合作不仅再次彰显了我们独特CRDMO商业模式中研究服务（Research）的价值，也证明了药明生物已成为研究服务领域的首选，助力包括中国制药企业在内的合作伙伴打造创新产品管线。此次合作也是双方携手共进的起点，未来将推动更多高质量生物药进入市场。我们也期待以‘药明生物’速度和效率赋能中国生物制药将其创新理念转化为前沿疗法，造福全球病患。
谢承润 先生
首席执行长
中国生物制药
这次合作是公司国际化战略的重要一步，我们非常高兴能够与药明生物达成研究服务合作，利用其全面高效的生物药发现解决方案。相信通过药明生物在抗体发现和工程领域的深厚专业知识，结合中国生物制药在生物学领域的丰富经验和在药物研发领域的强大实力，可以不断加速公司开发差异化的创新疗法，更好地惠及全球患者。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年6月底，药明生物帮助客户研发和生产的综合项目高达742个，其中包括16个商业化生产项目（不包括新冠项目和非活跃项目）。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。更多信息，请访问：www.wuxibiologics.com。
关于中国生物制药
中国生物制药有限公司是中国领先的创新研究和研发驱动型医药集团，业务覆盖医药研发平台、智能化生产和强大销售体系全产业链。产品包括多种生物药和化学药，在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域处于优势地位。
公司于2000年在香港联交所上市，股票代码为01177.HK。中国生物制药旗下企业分布于北京、上海、南京、连云港、青岛等地，拥有多个药品生产基地。公司成立至今，持续取得卓越成就和稳健发展，核心企业正大天晴药业集团、北京泰德制药股份有限公司均多年位列中国医药工业企业百强榜。
更多信息，请访问：https://www.sinobiopharm.com/
业务垂询
info@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics and Sino Biopharm Sign Discovery Service Agreement for First-in-Class Biologics
1
Sino Biopharm will have the exclusive rights to the monoclonal antibody (mAb) against undisclosed target, derived from WuXi Biologics' integrated discovery technology platforms
2
WuXi Biologics introduces new tailored service-based mode in integrated discovery services to enable client's global strategies
Shanghai,
December 30, 2024
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a service agreement with Sino Biopharm, a leading innovative R&D-driven pharmaceutical group in China, to discover a first-in-class mAb against an undisclosed target.
Under the terms of the agreement, WuXi Biologics will provide integrated discovery services, including antibody generation, lead identification and optimization, and developability assessment by leveraging its discovery technology platforms such as single B cell technology platform, which will enable Sino Biopharm to elect to an optimal preclinical mAb candidate with a designated target. Sino Biopharm will have the exclusive rights of the mAb generated from this collaboration and assume full responsibility for the Investigational New Drug (IND) applications, clinical trials and commercialization. WuXi Biologics will receive payments based on the progress of project development and commercialization.
Dr. Chris Chen
Chief Executive Officer
WuXi Biologics
We're delighted to provide our proven integrated discovery platforms for Sino Biopharm to discover a first-in-class mAb. This agreement further reinforces the value of R (research) in our unique CRDMO model and highlights WuXi Bio's role as the partner of choice in discovery services, including Chinese pharmaceutical companies in building innovative pipelines. It also strengthens the robust partnership between WuXi Biologics and Sino Biopharm. We look forward to offering global open-access technology platforms with unsurpassed speed and efficiency to support Sino Biopharm to transform their innovative ideas into new treatments for patients worldwide.
Mr. Tse, Eric S Y
CEO
Sino Biopharm
This cooperation marks a significant step in our company's internationalization strategy. We are extremely delighted to have reached a service agreement with WuXi Biologics, leveraging its comprehensive and streamlined suite of solutions for biologic discovery. We believe that by combining WuXi Biologics' profound know-how in antibody discovery and engineering together with Sino Biopharm's expertise in biology and strong capabilities in drug research and development, we can continuously accelerate the development of differentiated innovative treatments, thus better benefiting patients worldwide.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding 8 COVID CMO projects and 1 non-COVID dormant CMO project).
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
About
Sino Biopharm
Sino Biopharm is a leading innovation and R&D-driven pharmaceutical company in China, with its business covering the entire industrial chain of pharmaceutical R&D platforms, intelligent manufacturing, and a strong sales system. The product portfolio encompasses a variety of biopharmaceuticals and small molecule drugs, holding a dominant position in four major therapeutic areas of oncology, hepatology, respiratory and surgery/analgesia.
The company was listed on the Hong Kong Stock Exchange in 2000 with the stock code 01177.HK. The subsidiaries locate in Beijing, Shanghai, Nanjing, Lianyungang, Qingdao, and other cities, with multiple pharmaceutical production bases. Since its establishment, the company has consistently achieved remarkable achievements and steady development. The core enterprises, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd., have been both ranked among the top 100 Chinese pharmaceutical industrial enterprises for many years.
For more information, please visit: https://www.sinobiopharm.com/
Contacts
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
